Year-end Report (Q4) July 2025 – June 2026

StrongprogressinCancerTherapyand Noveltreatmentsofbacterialinfections

“We have reached major goals in the fields of Cancer Therapy and Novel Anti-infectives, two of the major causes of disease. Our goal is to make the new therapies available to patients through suitable commercial partnerships. Reaching Phase III studies has been a long-term goal and we have a strong pipeline of drug candidates in our portfolio to continue the translation of innovation into the clinic”, comments Catharina Svanborg, Chairman.

“We have maintained strong momentum across both therapeutic areas, with important advances. These achievements reflect the dedication of our teams and provide a solid foundation for continued progress in the coming period”, comments Jakob Testad, CEO.

The period in summary

FOURTHQUARTER,APR1,2026-JUN30,2026(THEGROUP)

–NetsalestotaledKSEK0(0)

–OtheroperatingincometotaledKSEK2(0)

–EBITDAamountedtoKSEK-13,384(-15,159)

–EBITamountedtoKSEK-15,937(-17,718)

–Earningspershare*wasSEK-0.0852(-0.0985)and-0.0838afterdilution

FULLYEAR,JUL1,2025-JUN30,2026(THEGROUP)

–NetsalestotaledKSEK0(0)

–OtheroperatingincometotaledKSEK55(208)

–EBITDAamountedtoKSEK-45,596(-44,663)

–EBITamountedtoKSEK-55,790(-55,126)

–Earningspershare*wasSEK-0.2984(-0.3076)and-0.2936afterdilution

–OnJune30,2026,theequity/assetsratio**was70.1(83.3)%

–CashamountedtoKSEK5,091(10,761)

*Profit/lossaftertaxfortheperioddividedby186,180,709(177,685,127),respectively189,245,925,where186,180,709isthenumberofsharesoutstandingonJune30,2026,and189,245,925sharesconstitutethenumberofsharesthattheCompanywillhaveifallsubscribedunitsintherightsissuearepaidandexercised.Thecomparativefigureinparentheseswasthenumber ofshares on June 30, 2025

**Equitydividedbytotalcapital.

SignificantEventsApr-Jun2026

10 June, 2026 –TheJournalofInfectiousDiseasespublishedthepaper“Targetingthediseaseresponse with NlpD and LytM for effective non-antibiotic treatment of urinary tract infections”.

22 June, 2026 –ClinicaltrialexpansionintheUS,incollaborationwiththeUniversityofIowa,totreathigh-risk, resistant, non-muscle-invasive bladder cancer (NMIBC).

25 June, 2026 –HamletBioPharmasecuresdrugmanufacturingatPhaseIIIqualityandreleaseofAlpha1H for distribution to clinical trial sites.

29 June, 2026 –HamletBioPharmaReceivesEuropeanRegulatoryApprovalforPhaseIIIStudyofAlpha1H in Bladder Cancer.

29 June, 2026 –HamletBioPharmaannouncedthatthedigitalanalyticsplatformBriefglancehashighlighted Hamlet BioPharma’s collaboration with the University of Iowa.

18 May, 2026 –HamletBiopharmaannouncedthesuccessfulgrantingofnewpatentsinJapanandIndia and a further patent allowance in Japan.

SignificantEventsJun2025-Mar2026

11 August, 2025 – Hamlet BioPharma, announced that the Extraordinary General Meeting resolved to approvetheBoardofDirectors’proposalforadirectedissueofsharesandwarrants(units).Theissuewill initially provide the Company with SEK 30 million and, if the warrants are fully exercised, may provide an additionalcapitalcontributionofapproximatelySEK110million.Intotal,thismeansthattheCompanymay raise up to SEK 140 million in new capital.

21 August, 2025 –HamletBioPharmaAnnouncestheCompletionoftheAlpha1HPhaseIIStudyinNon-Muscle Invasive Bladder Cancer.

10 November, 2025 –HamletBioPharmaReceivesFDAPivotal-StudyFeedbackforNovelNeoadjuvant Therapy in Non–Muscle Invasive Bladder Cancer

March 8, 2026 –HamletBioPharmasignedaLetterofIntenttooutlinetermsofapotentialcollaborationand a commercial agreement concerning Alpha 1H

March 24, 2026 –HamletBioPharmaraisesapproximatelySEK8.5millionthroughtheexerciseofwarrants of series TO5B, the so-called short-term warrants.

SignificantEventsafterthePeriod

5 August, 2026 –HamletBioPharmaraisedapproximatelySEK25.7millionthroughtheexerciseofwarrants of series TO5B.

July 16, 2026 – Discussions with a leading German pharmaceutical company regarding a partnership for bladder cancer treatment are progressing in a very positive manner.

OPENINGREMARKS

This year, Hamlet BioPharma and its close partner Linnane Pharma, have completed a complex and demanding phase of drug development, with great success. Major goals, barely visible on the horizon when the company was listed on Spotlight market, have now been reached and the novel treatments developedby us have become a reality. Three controlled Phase II trials in patients with cancer or infections have been completed, showing successful treatment effects and suggesting a great commercial potential.

Cancer therapy: The investigative new drug Alpha1H kills cancer cells by inducing apoptosis and has shown therapeutic efficacy without significant side effects. Alpha1H is Hamlet BioPharma’s Phase III-ready oncology asset for a first in class neoadjuvant therapy for patients with low risk non–muscle invasive bladder cancer (NMIBC).HamletBioPharmahasreceivedpositivefeedbackfromtheUSFoodandDrugAdministration(FDA) andtheEuropeanMedicinalAuthority(EMA)toconductstudiesinEuropeandtheUS,theclinicalPhaseIIItrial infrastructure is established and drug production at Phase III quality completed.

Inaddition,newstudiesadvancetheclinicaldevelopmentofAlpha1H.HamletBioPharmahasrecentlysigneda clinicaltrialagreementwiththeUniversityofIowa,oneoftheleadingU.S.centersforbladdercancerresearchand therapy.ThenewstudyofAlpha1HaddressesCarcinomaInSitu(CIS);aseveresurface-spreadingandtherapy-resistant form of bladder cancer where patients may need to remove their bladders to avoid systemic disease.

The company’s immediate goal in the cancer area is to conduct the Phase III studies, obtain market approval for Alpha1H as a treatment for bladder cancer and reach the market. We are also extending the clinical studies to include patients with more severe bladder cancer, in collaboration with leading investigators in the US.

Ongoing, positive partnering discussions with a majorpharmaceutical company in the bladder cancer field, under a letter of intent, are addressing the commercialization of the bladder cancer asset Alpha1H. The dialogue with our potential partner has been very constructive and forward-looking.

Infectious disease therapy: The positive results of the clinical studies are further driving a shift in infectious disease management. The four assets targeting the disease in the infected patient are effective against both antibiotic-sensitive and resistant pathogens. A successful Phase II clinical study showed a reduction in symp-toms and recurrences and increase in quality of life and the results were published in a leading international journal.

Additionally,immunotherapyhasshownpositiveeffectsonchronicpain,inpatientswithbladderpainsyndrome. Clinical data from the Phase II study show a reduction in pain scores and an improved quality of life in patients treatedwithanIL-1receptorantagonist,affectingnervecellactivationandpain.Molecularadvancesalsomake it possible to understand the cause of disease and define patient groups suitable for therapy.

Commercial development: The focus of the bladder cancer project is on completing the clinical development and establishing the right commercial framework for market access. Partnering with an established marketing organization would position us to deliver long-term value to patients, healthcare systems and shareholders, subject to successful study outcomes and market approval.

The company’s immediate goal is also to extend the clinical studies to include more severe bacterial infections and to take the new anti-infective drug candidates to the clinic. Partnering discussions are ongoing also for these projects. Hamlet BioPharma recently signed a partnering agreement with the South Korean company ImmunoForge to access drug release technology.

The company recently raised additional Funds through warranties. We are grateful for the strong investor support and will continue to use our capital effectively for optimal development and commercialization of our drugs. To date, the company has delivered three successful Phase II studies on a budget of about SEK 300 million,includingthecancerprojectinPhaseIIIandthesuccessfuldevelopmentofalternativestoantibiotics.

Thistrackrecordshouldconvinceinvestorsofthecompany’sabilitytodeliveronstrategicgoalsatlowcostand high quality. We would like to thank our multi-national team, as well as our external partners and collaborators, who are behind the successes and remain a resource for the future.

Jakob TestadCatharinaSvanborg

CEOChairmanoftheBoard

EVENTS

NOVELTREATMENTSOFBACTERIALINFECTIONS

On September 4, 2025 –HamletBioPharma,announcedthePhDthesisdefensebySamudraSabari,M.Sc. Title ‘’Tumor response mechanisms and treatment effects of alpha1-oleate’’

On October 24, 2025 –HamletBioPharmaannounceddetailedinformationfromthelarge-scaleinternational study in infants with severe kidney infections. The large, international study, conducted by scientists and clinicians in Sweden and Singapore involved over 160 infants with their first febrile urinary tract infection and provides one of the most comprehensive molecular data sets ever generated for acute pyelonephritis.

The advanced methodology and the way the clinical study was performed reshape the understanding of severe urinary tract infections (UTIs) and open new paths for treatment beyond antibiotics.

On October 24, 2025 – Hamlet BioPharma announced that the new molecular concepts for the treatment of bacterial infections were presented at the National Infection Biology meeting, held on October 20-21. Scientists collaborating with Hamlet BioPharma AB, have developed several drug candidates and demon-strated their potent treatment effects in models of severe infections.

On November 5, 2025 – Hamlet BioPharma published a newsletter clarifying how a clinical study in infants with febrile kidney infection supports Hamlet BioPharma’s strategy for non-antibiotic treatment of bacterial infections. An international clinical study in infants experiencing their first febrile urinary tract infection included more than 160 infants in Sweden and Singapore. Genome wide technology and a strict clinical pathwaymakesthisoneofthemostdetailedstudieseverperformedanddemonstratesthatsevereinfection andkidneyinjuryaredrivenbyanexcessiveimmunereactiontoinfection—notbythebacteriathemselves.

On January 16, 2026 –HamletBioPharmawelcomedinterestedpartiestotheSymposium“Novel Treatments for Infections and Cancer” that took place on the 21st of January. The invited speakers are leading inter-national scientists fromthe U.S. with a background in infection biology and scientists fromLund University, sharing cutting-edge research and future perspectives on novel therapies for bacterial infections and cancer.

On February 23, 2026 – Nature Microbiology published the paper ‘’Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.’’ the paper was accepted on February 12th.

This groundbreaking study introduces a new approach to managing recurrent urinary tract infections.Instead of killing the bacteria, the treatment focuses on targeting and calming the disease response. Clinical efficacy of this approach is demonstrated in this study, showing effects comparable to standard antibiotic therapy.

This discovery could also mark a major conceptual breakthrough in the fight against antibiotic resistance and the future treatment of infections.

On February 3, 2026 – Hamlet BioPharma signed a collaboration agreement with the Korean biotech company ImmunoForge, to develop novel drug delivery technology for the peptide drug NZX, for use in patents with tuberculosis.

ImmunoForgebasedinSeoul,SouthKorea,contactedHamletBioPharmatoinitiatethiscollaboration.

The company who are developing novel drug delivery techniques forclinical use, will develop novel adminis-tration technology for the NZX peptide, specifically a slow-release technology that would prolong the effectof each treatment.

Thefuturerightstotheresultsofthecollaborationwillbejointlyownedbythetwocompanies,aswellas future patent rights.

On June 10, 2026 –TheJournalofInfectiousDiseasespublishedthepaper“Targetingthediseaseresponse with NlpD and LytM for effective non-antibiotic treatment of urinary tract infections.” This study demonstrates that inhibiting the disease response of the host offers an efficient alternative to antibiotics forthe treatment of bacterial infections. By inhibiting the disease response to infection and accelerating bacterial clearance, the drug candidates protect infected tissues from disease, with similar efficacy as antibiotics. https://doi.org/10.1093/infdis/jiag243

CANCERTHERAPY

On August 21, 2025 –HamletBioPharmaAnnouncestheCompletionoftheAlpha1HPhaseIIStudyin

Non-MuscleInvasiveBladderCancer.ThecompletionofthesuccessfulPhaseIIclinicaltrialofthecompany’s drug candidate Alpha1H in patients with cancer in the urinary bladder. The final clinical study report basedon extensive analyses of clinical and laboratory data highlights the potent treatment effects. All primary and secondary endpoints of safety and efficacy were reached.

On September 9, 2025 – Hamlet BioPharma, announces the successful granting of new patents, strength-ening its intellectual property portfolio, reaffirming its position at the forefront of technological innovation. FivenewpatentsinAustralia,China,India,Japan,andtheUShavebeengrantedsincethepressreleaseon 7 April 2025, which announced three new patents.

On September 22, 2025 – Hamlet BioPharma, announced the successful production of a first batch of Alpha1H,thedrugcandidatetargetingBladderCancer,atPhaseIIIquality.Thebatchisnowundergoing final evaluation steps, before release for clinical use.

On March 6, 2026 –HamletBioPharmasignedaLetterofIntenttooutlinetermsofapotentialcollaboration and a commercial agreement concerning Alpha 1H.

Hamlet signed a non-binding Letter of Intent (LoI) with an undisclosed company specializing in uro-oncology basedinnorthernGermany.Thepurposeistooutlinetermsandconditionsforthecompletionofdevelopment and for global commercialization of Alpha 1H in the field of bladder cancer.

On June 17, 2026 – Hamlet BioPharma conducted a pre-initiation visit at the Department of Urology at CharlesUniversity,Prague,ledbyProfessorMarekBabjuk,akeyinternationalopinionleaderinbladder cancer therapy. Prague is an important center for bladder cancer research and trials of novel therapies, and the trial technology and collaboration with Hamlet BioPharma and Lund University is established.

ProfessorBabjuk’sgroupconductedtherecentlycompleted,successfulPhaseIIstudyofAlpha1Hinpatients with non-muscle invasive bladder cancer (NMIBC). The Phase III study strengthens the commercial potential of Alpha1H and the future market opportunities for the drug.

On June 22, 2026 –HamletBioPharmaannouncedthesigningofaclinicaltrialagreementwiththeUniversity of Iowa, one of the leading U.S. centers for bladder cancer research and therapy. The new study advances the clinical development of Alpha1H, a human breast milk derived treatment for bladder cancer, to include Carcinoma In Situ (CIS); a severe surface-spreading and therapy-resistant form of bladder cancer where patients may need to remove their bladders to avoid systemic disease.

On June 25, 2026 – Hamlet BioPharma Announces the successful release of the Phase III quality batch of Alpha1H for use in clinical trials of bladder cancer in Europe and the US. Large-scale manufacturing of Alpha1Hhasbeenestablishedsincethestartoftheclinicalprogram,withanincreaseinvolumesandtech-nical adjustments during successive phases of the program. The production at Phase III quality requires an extensive and complex development process, which now has been completed.

On June 29, 2026 – Hamlet BioPharma announced that the digital analytics platform Briefglance has high-lightedHamletBioPharma’’scollaborationwiththeUniversityofIowaregardingthedevelopmentofAlpha1H treatment for patients with severe bladder cancer. The article outlines the advanced scientific and clinical background, the importance of the collaboration and its significance for Hamlet BioPharma.

Among other observations, Briefglance describes Alpha1H as a promising treatment candidate for patients who do not respond to BCG therapy; a patient population for whom treatment options remain limited.

On June 29, 2026 – Hamlet BioPharma announced regulatory approval from the European Medicines Agency(EMA)foritsPhaseIIIclinicalstudyofAlpha1Hinbladdercancer.Theapprovalrepresentsamilestone crucial for the clinical development of Alpha1H and provides a clear regulatory path toward a potential future marketing application in Europe.

COMPANYANDFINANCE

On July 17, 2025 – Hamlet BioPharma proposes to raise capital through a directed new issue of B shares with associated warrants (so-called units). A unit consists of a B share with a short and a longer warrant. TheissueinitiallyaddsjustoverSEK30millionand,ifthewarrantsarefullyexercised,canprovideafurther capital injection of a total of approximately SEK 110 million, which means that the company can add up to SEK 140 million in new capital in total. The issue is aimed at approximately 20 external investors and the

subscription price per unit is SEK 4.30. The subscription price corresponds to the average volume-weighted share price during 30 trading days of SEK 4,30. The subscription price for the short option that runs for

12monthsisSEK6pershareandthesubscriptionpriceforthelongoptionthatrunsfor30monthsisSEK10 per share. Dilution after full subscription is calculated at just over 10%. Hamlet BioPharma has received binding subscription commitments from all external investors.

On July 24, 2025 –HamletBioPharmacalledforanExtraordinaryGeneralMeetinginHamletBioPharmaAB to be held on August 11th, 2025.

On August 11, 2025 – Hamlet BioPharma, announced that the extraordinary general meeting decided to approve the board’s proposal for a directed new issue of shares and warrants (units). The issue initially providesthecompanywithSEK30millionand,ifthewarrantsarefullyexercised,mayprovideanadditional capitalinjectionofapproximatelySEK110million.Thismeansthatthecompanycanbeprovidedwithatotal of up to SEK 140 million in new capital.

On August 28, 2025 –HamletBioPharmareleasedtheyear-endreport(Q4)

On September 12, 2025 – The directed issue was registered with the Swedish Companies Registration OfficeandthenumberofseriesBsharesinthecompanyhasincreasedby6,976,744andthesharecapital hasincreasedbySEK69,767.44fromSEK1,776,851.27toSEK1,846,618.71.Thenumberofsharesinthe companynowamountsto184,661,871,ofwhich39,947,938areseriesAsharesand144,713,933areseries Bshares.

On March 15, 2026 –Anewsupplementarysubscriptionperiodwasannounced,from16-23ofMarch2026. TheBoardofDirectorshaddecidedtoadjustthetermsandconditionsforwarrantsofseriesTO5Baheadof the next subscription period, which runs from 20 July to 31 July 2026.

On March 24, 2026 –HamletBioPharmaannouncedthatthecompanyhadreceivedapproximately 9 million SEK through subscription of warrants series TO5B, before issue costs.

On February 13, 2026 –HamletpublishedtheQ2interimreportforOctobertoDecember2025.

On May 18, 2026 –HamletBiopharmaannouncedthesuccessfulgrantingofnewpatentsinJapanandIndia and a further patent allowance in Japan. This continued strengthening of Hamlet BioPharma’s international intellectual property portfolio reaffirms its position at the forefront of technological innovation.

On May 22, 2026 –HamletpublishedtheQ3interimreportforJanuarytoMarch2026.

INVESTORRELATIONS

Duringthefiscalyear2025/2026,HamletBioPharmahascontinueditsseriesofdigitalinvestormeetingsheld onJuly25th,August28th,September25th,October31stNovember14th,January21st,February13th,March 18th, April 23rd, May 22nd and June 23rd.

On March 30, 2026 –ItwasannouncedthatHamletBioPharmapresentedattheFinancialStockholmevent on March 26, 2026.

ADDITIONALSIGNIFICANTEVENTSAFTERTHEFORTHQUARTER

On July 16, 2026 – Hamlet BioPharma constructive and forward-looking discussions with the potential partner in bladder cancer with negotiations regarding the terms and framework for completing the drug development and commercialization of Alpha1H together with a leading German pharmaceutical company. ThediscussionsfocusonthetreatmentofbladdercanceracrossmultipleEuropeanmarkets.Furtherdiscus-sions are underway regarding other markets.

On July 24, 2026 –HamletBioPharmaannouncedthatthedigitalbusinessmagazinesTimeBusinessNews andUSAWirehavebothhighlightedHamletBioPharma’’scollaborationwiththeUniversityofIowaregarding the development of Alpha1H treatment for patients with severe bladder cancer. The article outlines the advanced scientific and clinical background, the importance of the collaboration and its significance for HamletBioPharma.

On July 28, 2026 –HamletBiopharmaannouncedthegrantandimpendinggrantofnewpatentsintheUS andJapan.

ThestrengtheningofHamletBioPharma’sintellectualpropertyportfolioreaffirmsitspositionattheforefront oftechnologicalinnovation.ThenewpatentsandallowancescoverbreakthroughsintheHAMLETfamilyof drug candidates, which effectively kill cancer cells and growing tumor tissue with high precision, as well as the company’s Interleukin-1 (IL-1)-related technology for the treatment of bladder pain.

On August 5, 2026 – Hamlet BioPharma announced the preliminary outcome of the exercise of warrants of series TO5B. Based on subscriptions registered to date, the company will preliminarily receive SEK 25,698,036beforeissuecoststhroughthesubscriptionof4,283,006newClassBsharesatasubscription price of SEK 6 per share.

COMPANYOVERVIEW

Hamlet BioPharma is a pharmaceutical company focused on developing innovative treatments for cancer and infectious diseases. With a mission to address large, unmet medical needs, the company has built a robust pipeline of therapeutic candidates, in collaboration with Linnane Pharma and Lund University, targeting malig-nant tumors and antibiotic-resistant infections. These advances underscore Hamlet BioPharma’s potential in innovative drug development that addresses important medical needs.

Strongclinicalpipelinewithadvancedassetsinbladdercancer,infection,andpain.

Powerfuldiscoveryplatformdrivinginnovationsinoncologyandantibacterialtreatments.

Provendrugdevelopmentexpertise,offeringvaluablelong-termpartnershipopportunities.

BLADDERCANCERTHERAPY

MARKETPOTENTIALBLADDERCANCER

Theneedforeffectivenewdrugsagainstcancerandinfectionsishugegloballyandisconstantlyincreasing. Hamlet BioPharma’s drug candidates are well positioned to capture significant shares in these fast-growing markets and to address critical needs and position itselffor sustainable growth.

Alpha1H,withitspromisingclinicalresultsandimmuneactivationprofile,iswellsuitedtoaddresstheneedfor novelNMIBCtreatmentandtobecomeavaluableassetfortheglobalbladdercancermarket.Itsinnovative mechanism ofaction – targeting cancer cells while sparing healthy tissue – could make Alpha1H a preferred alternative to traditional treatments, which are often associated with high toxicity and frequent relapses.

MarketsizeSuperficialBladderCancer2023-2034

Source: Transparency Market Research; https://www.transparencymarketresearch.com/non-muscle-invasive-bladder-cancer-market.html

TREATINGBACTERIALINFECTIONSWITHOUTANTIBIOTICS

Peptide-induced response in mycobacteria

Mycobacteria treated with NZ2114 peptide for 24 hours, visualized with scanning electron microscopy.

The bacterial membrane is destroyed by NZ2114.

The antimicrobial peptide NZX is being developed as a drug candidate for pulmonary tuberculosis treatment. Thenew,peptide-baseddrughasshownpromisingtreatmenteffectsagainstlungtuberculosisinanimalmodels, both against antibiotic sensitive and antibiotic-resistant Mycobacterium tuberculosis bacteria. The peptide eliminated M. tuberculosis in an animal model of tuberculosis with an 81.14% reduction after three doses, compared to untreated controls.

TREATMENTOFCHRONICPAIN

HamletBiopharma’soverallgoalisto

•reachthemarketwithPhaseIIIreadyassetsincancerandinfection

•drivetheclinicaldevelopmentofgroundbreakingpreclinicalassetswithproven therapeutic efficacy in animal models through clinical trials to partnering.

Financing

-Phase III ready asset Alpha1H

FDAandEMAmarketapproval

-Phase II validated infectionandpainindications New indications for established drug

-Buildingthecompany Partnering

-SpecialistorBigpharma,providersofmarketaccess

-Developmentofpreclinical/clinicalassets

THEINFECTIONTREATMENTMARKET

HamletBioPharmaoffersagroundbreakingsolutiontoaddressingtheproblemofseverebacterialinfections and antibiotic resistance. By focusing on the disease rather than the bacteria, the advances could lead to a paradigmshiftinthetreatmentofbacterialinfections.Thepatient’shealthcanthusbeimproved,andbacteria can be cleared through normal defense mechanisms, rather than directly targeting the bacteria. In this way, infectionscausedbyantibiotic-resistantandantibiotic-sensitiveorganismscanbetargetedinanimalmodels. This approach also reduces the selective pressure that contributes to resistance in the environment and the generalpopulation.

Market size Recurrent Acute Cystatis and Bladder Pain Syndrome 2023-2034

Source: Data are estimated values to represent market development from reports and research from the American Urological Association (AUA) and International.

FINANCIALOVERVIEW

Revenue

Hamlet Biopharma is specializing in the development of drugs with a broad and strong portfolio of projects forthetreatmentofcancerandinfections.Thecompanyremainspre-revenue,withvaluecreationdrivenby milestones in development and partnerships. Net sales amounted to KSEK 0 (0) during the quarter, and to KSEK 0 (0) during the full year. Other operating income amounted to KSEK 2 (0) during the quarter, and to KSEK 55 (208) during the full year.

Earnings

External costs were related to the continued drug development activities of the research team at Lund University. The team at Lund University is also responsible for the development of manufacturing methods, stability testing, and chemical and functional characterization of existing and new drug substances and plays a key role in the coordination of laboratory testing in the clinical trial. EBITDA for the quarter amounted to KSEK-13,384(-15,159),andforthefullyearKSEK-45,596(-44,663).Thedepreciationsinthequarterwere KSEK-2,553(-2,560),andforthefullyearKSEK-10,194(-10,462).EBITforthequarteramountedtoKSEK

-15,937(-17,718),andforthefullyearKSEK-55,790(-55,126).NetresultforthequarterwasKSEK-15,863 (-17,496), and for the full year KSEK -55,562 (-54,653).

Financialposition

Attheendofthefourthquarter,theequity/assetsratiowas70.1(83.3)%,andtheCompany’scashandcash equivalents were KSEK 5,091 (10,761).

OnApril2,2026,aportionoftheoutstandingTO5Bwarrantswasexercisedpriortotheirscheduledexpira-tion.TheCompanyreceivedSEK9.1million,netofissuecostsofSEK0.035million.

Followingtheendofthequarter,thesubscriptionperiodfortheremainingwarrantswasheldfromJuly20to July 31, 2026. The exercise of the warrants will provide the Company with proceeds of SEK 25.7 million.

Investments

TheCompanydoesnotcapitalizeexpensesforresearchanddevelopmentasassets,sincetheCompanyis in an R&D stage. R&D costs are therefore recognized as operating expenses in the income statement.

Depreciation

Duringthequarter,depreciationofequipmentamountedtoKSEK33(39),andthedepreciationofpatents from the merger with SelectImmune Pharma AB amounted to KSEK 2,021 (2,021).

Inthegroup,depreciationofpatents,includingtheacquisitionofLinnaneProjectsAB,amountedtoKSEK 2,553 (2,520) during the quarter.

Employees

Thecompanyhadtheequivalentof6(7)full-timeemployeesduringthequarter.

Theshare

TheCompany’sshareshavebeentradedonSpotlightStockMarketsinceOctober23,2015.Theshareis traded under the short name “HAMLET B” with ISIN code SE0015661152.

AttheextraordinarygeneralmeetinginHamletPharmaABonMarch2,2021,itwasdecidedthatthecompa-ny’s common shares would undergo a split with relation 3:1 and would be reclassified as A- and B-shares.

The B-shares will be traded on Spotlight Stock Market. The A-shares will not be listed. Each A-share entitles totenvotesandB-sharesentitlestoonevote.Furthermore,itispossibleforshareholderstoconvertA-shares to B-shares, which can be traded on Spotlight Stock Market. This conversion program is ongoing with no current deadline. This means that the ratio between A- and B-shares will change over time.

As of June 30, 2026, the number of shares registered at the Swedish Companies Registration Office (Bolagsverket)totaled186,180,709.Theregisteredcurrentratioofshareswas39,911,660A-sharesand 146,269,049B-shares.

Subscriptionwarrantsorguarantees

The warrants in serie TO5B and serie TO6B gave the right to subscribe for a total of 20 930 232 shares. ByJune302026,thereare11,560,798shareslefttobeexercised.Theissuewasaimedatapproximately

20externalinvestors.Thesubscriptionpricefortheshortoptionwithatermof12monthsisSEK6pershare andthesubscriptionpriceforthelongoptionwithatermof30monthsisSEK10pershare.Theoptionsare not admitted to trading.

Transactionswithrelatedparties

Duringthequarter,KSEK1,959(1,459)waspaidtoLinnanePharmaAB,ofwhichKSEK1,839(1,339)refers to the co-operation agreement, KSEK 120 (120) refers to patent license.

The co-operation agreement with Linnane Pharma refers to compensation for access to advanced science and cutting-edge technology for drug development. The collaboration means that Linnane Pharma’s techno-logy platform and other resources are available to Hamlet BioPharma. Hamlet BioPharma is a subsidiary company of Linnane Pharma AB, which owns 32.75% of the capital and 73.80% of the votes of Hamlet Bio-Pharma.

Furthermore, salaries and allowances to board and management were paid during the period. Transactions with related parties are on market terms.

Significantrisksanduncertainties

The Board’s assessment of significant risks and uncertainties is unchanged compared with the most recent financial year and are described in the most recently published annual report (2025-06-30).

BasisofpreparationfortheYear-EndReport

The Company prepares its accounts in accordance with the Swedish Annual Accounts Act (Årsredovisning-slagen) and the K3 framework (BFNAR 2012:1) of the Swedish Accounting Standards Board (Bokföringsnämnden).

The company’s accounting principles are unchanged compared with most recent financial year and are described in the most recent published annual report (2025-06-30).

On March 31st, 2023, Hamlet BioPharma acquired Linnane Projects AB from Linnane Pharma AB and the patents and know-how regarding a new peptide-based drug against tuberculosis as well as the know-how requiredtodeveloptheproject.OnNovember7,2025,HamletBioPharmaestablishedthesubsidiaryAlpha 1H BC AB. In accordance with regulations at Spotlight and the Swedish Accounting Standards Board (Bokföringsnämnden),consolidatedaccountsofLinnaneProjects,Alpha1HBCABandHamletBioPharma are drawn up.

Generalmeetingandannualreport

Thegeneralmeetingfor2025/2026isplannedtobeheldatHighCourtinMalmöonNovember202026.

Theannualreportwillbeavailableatthecompany’soffice,Klinikgatan32inLundfortheshareholders three weeks before the meeting. The documents are then also published on the company’s website (https://hamletbiopharma.com) and are then sent to the shareholders who request it and state their postaladdress.

Theboardproposesthatnodividendbepaidforthefinancialyear2025/2026.

Review

Thisinterimreporthasnotbeenaudited.

Financialcalendar

AnnualReportfor2025/2026October30, 2026

Interim report for Q1, 2026/2027November13,2026 AnnualGeneralMeetingfor2025/2026November20,2026

INCOMESTATEMENT:THEGROUP

BALANCESHEET:THEGROUP

CASHFLOWSTATEMENT:THEGROUP

EQUITY:THEGROUP

INCOMESTATEMENT:THEPARENTCOMPANY

BALANCESHEET:THEPARENTCOMPANY

CASHFLOWSTATEMENT: THE PARENT COMPANY

EQUITY:THEPARENTCOMPANY

TheBoardofDirectorsandtheChiefExecutiveOfficerassurethattheinterimreport providesatrueandfairviewoftheCompany’soperations,position,andresults.

Malmö,August28,2026

CatharinaSvanborgJakobTestad

ChairpersonoftheBoardCEO

BillHanssonMagnusNylén

BoardmemberBoardmember

HenrikSundin

Boardmember

Forfurtherinformation:

HamletBioPharmaAB

Klinikgatan32

222 42 Lund hamletbiopharma.com

CatharinaSvanborg,ChairmanoftheBoard

Tel:+46(0)7094265 49

E-mail:catharina.svanborg@hamletpharma.com

JakobTestad, CEO

Tel:+46(0)7084842 10

E-mail:jakob.testad@hamletbiopharma.com